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The objective of this clinical study was to assess the safety and feasibility of the collagen scaffold, NeuroRegen scaffold, one 
year after scar tissue resection and implantation. Scar tissue is a physical and chemical barrier that prevents neural regeneration. 
However, identification of scar tissue is still a major challenge. In this study, the nerve electrophysiology method was used to 
distinguish scar tissue from normal neural tissue, and then different lengths of scars ranging from 0.5–4.5 cm were surgically 
resected in five complete chronic spinal cord injury (SCI) patients. The NeuroRegen scaffold along with autologous bone 
marrow mononuclear cells (BMMCs), which have been proven to promote neural regeneration and SCI recovery in animal 
models, were transplanted into the gap in the spinal cord following scar tissue resection. No obvious adverse effects related to 
scar resection or NeuroRegen scaffold transplantation were observed immediately after surgery or at the 12-month follow-up. 
In addition, patients showed partially autonomic nervous function improvement, and the recovery of somatosensory evoked 
potentials (SSEP) from the lower limbs was also detected. The results indicate that scar resection and NeuroRegen scaffold 
transplantation could be a promising clinical approach to treating SCI. 
NeuroRegen scaffold, chronic spinal cord injury, scar resection, collagen scaffold transplantation, bone marrow mon-
onuclear cells, tissue regeneration 
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INTRODUCTION 
Spinal cord injury (SCI) results in the permanent impair-
ment or loss of voluntary motor function and sensation be-
low the level of injury, and effective treatment remains one 
of the most daunting challenges in neuroscience. The annual 
incidence of SCI is about 40 cases per million people, 
mainly due to motor vehicle crashes, falls, sports, and vio-
lent acts (Chen et al., 2013). Primarily affecting young 
adults, SCI tremendously impacts their personal, social, and 
professional lives, leading to considerable financial, emo-
tional, and psychological burdens on the patients and their 
families (Selvarajah et al., 2014). The current therapeutic 
methods for SCI mainly aim to prevent further damage to 
the injured spinal cord and include operative decompres-
sion, injured lesion stabilization and fusion, and rehabilita-
tion (Wilson et al., 2013). Although these approaches ex-
tend patient’s lifespan, there are no clinical treatments tar-
geting neural regeneration following SCI (Garcia-Altes et 
al., 2012).  
Nerve tissue in the injured mammalian peripheral nerv-
ous system exhibits the capacity to lead axons to their syn-
aptic targets based on the removal of myelin debris by im-
mune cells and cytokine secretion by Schwann cells 
(Schmidt and Leach, 2003). However, SCI leads to scar 
formation composed of myelin, cellular debris, microglia, 
astrocytes, oligodendrocytes, meningeal fibroblasts, and 
extracellular matrix molecules, all of which hinder the re-
generation of axons across the injured site (Bahr et al., 
1995; Hermanns et al., 2001). Molecules expressed by reac-
tive cells in the scar, such as chondroitin sulfate proteogly-
cans (CSPGs), contribute to the scar’s effects on axon re-
growth (McKeon et al., 1995). These molecules exert their 
inhibitory effects by binding to the axon’s cell surface or 
antagonizing trophic factors and cell adhesion molecules 
that are essential for axonal regeneration (Levi et al., 1994). 
Hence, scars are regarded as both a physical and a chemical 
barrier that prevent nerve regeneration following SCI 
(Fawcett and Asher, 1999; Yiu and He, 2006).  
Many studies have modulated the gliotic scarring re-
sponse by enzymatic digestion, antibody blocking, or clonal 
deletion of specific glial scar molecules to promote axon 
regeneration and functional SCI recovery (Bradbury et al., 
2002; Goldshmit et al., 2004; Shearer et al., 2003). Alt-
hough these biochemical approaches show promise, the 
therapeutic effects are relatively limited because of the mul-
tiple molecule candidates and complicated scar microenvi-
ronment. Compared to biochemically altering gliotic re-
sponses, surgical scar resection is a more direct approach to 
eliminate the inhibitory effect of scarring on nerve regener-
ation after SCI. However, a method for identifying the scar 
tissue in SCI patients has not been reported, and the resec-
tion procedure may lead to further injury if the scar tissue is 
not precisely identified (Rasouli et al., 2009). In this work, 
intraoperative neurophysiological monitoring was used to 
distinguish the scar tissue from normal neural tissue. The 
combination of intraoperative neurophysiological monitor-
ing with surgical scar resection may provide a safe and ef-
fective method to eliminate the inhibitory effects of scarring 
in patients with chronic SCI.  
Biomaterial scaffolds can be used to bridge the lesion site 
in patients with SCI, providing a structural platform to fa-
cilitate axonal growth and also a vehicle to deliver stem 
cells and functional biomolecules to favorably reconstruct 
the microenvironment at the injury site (Haggerty and 
Oudega, 2013). A linearly ordered collagen scaffold termed 
NeuroRegen scaffold was found to induce axonal growth 
along collagen fibers and inhibit scar formation after im-
plantation in animal studies. In the past 10 years, the Neu-
roRegen scaffold has been used to deliver multiple func-
tional molecules such as neurotropic factors and antibodies 
to the injured site in SCI animal models. Newborn neurons, 
electrical conductivity, re-myelination, and motor function 
recovery were observed in both rat and canine SCI models 
(Han et al., 2009; Han et al., 2010; Han et al., 2015; Li et 
al., 2015; Lin et al., 2006). The NeuroRegen scaffold prod-
uct standard has been established and the third party inspec-
tion of safety evaluation by the National Institute of Food 
and Drug Control has been completed in order to lay the 
foundation for the clinical study.  
Bone marrow is regarded as a source of multiple stem 
and progenitor cells, and bone marrow-derived mesenchy-
mal cells can promote SCI recovery by producing numerous 
neurotropic factors or immune cytokines (Majka et al., 
2001). Since 2005, a number of clinical trials have evaluat-
ed the safety and efficacy of autologous bone marrow cell 
transplantation in acute and chronic SCI patients (Deda et 
al., 2008; Geffner et al., 2008; Jarocha et al., 2014; Kara-
mouzian et al., 2012; Park et al., 2005; Sykova et al., 2006; 
Yoon et al., 2007). 
In this study, we first took advantage of intraoperative 
neurophysiological monitoring to identify and surgically 
resect scar tissues ranging from 0.5–4.5 cm in five complete 
chronic SCI patients, and then the NeuroRegen scaffold 
with autologous bone marrow mononuclear cells (BMMCs) 
was implanted into the resection sites. The clinical study 
was approved by the ethics committee and registered on the 
National Institute of Health database (ClinicalTrials.gov: 
NCT02352077). All procedures performed in this study 
were in accordance with the ethical standards of a human 
clinical study. We analyzed the safety and potential efficacy 
of scar resection and scaffold transplantation during a 
one-year period. The results provide the first evidence that 
scar resection with nerve electrophysiology monitoring and 
subsequent biomaterial scaffold implantation might be a 
promising clinical approach to rebuilding a regenerative 
microenvironment for SCI repair.  
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RESULTS 
Linear and ordered structure of NeuroRegen scaffold 
fibers 
The NeuroRegen scaffold fibers fabricated in this study 
were arranged linearly to effectively guide the orientated 
growth of axons (Figure 1). There are many tiny collagen 
fibers in a single fiber, which may increase the space for 
cell attachment and ingrowth. The biological safety of the 
NeuroRegen scaffold was evaluated by the National Insti-
tute of Food and Drug Control, which meets the Chinese 
Criterion of Medical Device GB16886. 
Patients 
Five patients with chronic traumatic SCI who met the inclu-
sion criteria were enrolled in our study. Their demographic 
information is shown in Table 1. All patients were classified 
as American Spinal Injury Association (ASIA) Impairment 
Scale grade A and had complete injuries in cervical or tho-
racic spinal cord segments. 
 
 
Figure 1  Linear and ordered structure of the NeuroRegen scaffold.     
A, Photo of NeuroRegen scaffold. Scale bar=1 cm. B, SEM image exhibit-
ing microstructure of a single NeuroRegen scaffold fiber. Scale bar=100 
μm. 
Scar resection under neural electrophysiology 
monitoring 
After opening the dura mater, the injured spinal cords were 
filled with scar tissue. Because it is difficult to distinguish 
the boundaries between normal spinal cord tissue and scar 
tissue, we developed a new strategy using somatosensory 
evoked potentials (SSEP) and motor evoked potentials 
(MEP) to identify rostral and caudal edges of the scar, and 
then the scar was resected. The lengths of scars in individu-
al SCI patient ranged from 0.5–4.5 cm (Table 2). Following 
scar tissue resection, the NeuroRegen scaffold with BMMCs 
was transplanted into the spinal cord gap (Figure 2). Histo-
logical examination of the resected scar tissue showed 
strong positive immunohistochemical staining for CSPGs 
and vimentin, and negative immunohistochemical staining 
for NF, nestin, Tuj-1, and S100 (Figure 3). These results 
demonstrated that the dissected tissue mainly consisted of 
scar tissue. 
Safety assessment of scar resection and NeuroRegen 
scaffold transplantation 
Safety is a major concern regarding scar resection and 
NeuroRegen scaffold transplantation. Despite the different 
lengths of dissected scars, there were no increases in the 
ASIA Impairment Scale grade, sensation, or motor level 
after surgery (Table 2), and no obvious neurological deteri-
oration was detected during follow-up. Adverse effects in-
cluding fever, infection, allergic reaction, and perioperative 
complications (anesthesia-related complications) were ob-
served to assess the safety. There were no significant ad- 
verse effects related to scar resection or NeuroRegen scaf-
fold transplantation immediately after the surgery or 12 
 
 
Figure 2  Surgical procedures and scar resection diagram. A, The spinal cord was exposed after opening the dura mater, and the asterisk (*) indicates the 
gap after scar tissue resection. Scale bar=1 cm. B, The NeuroRegen scaffold with BMMCs was transplanted into the spinal cord gap. Scale bar=1 cm. C, 
Diagram of the scar resection guided by SSEP (blue color) and MEP (red color). 
650 Xiao, Z., et al.   Sci China Life Sci   July (2016) Vol.59 No.7 
 
Figure 3  Immunofluorescence staining of dissected scar tissue. The antibodies in panels A-F are neurofilament 200 kD (NF), nestin, β-tubulin III (Tuj-1), 
S100 protein, chondroitin sulfate proteoglycans (CSPGs), and vimentin, respectively. Scale bar=2 mm. 
months postoperatively (Table 3). These results demonstrate 
the safety of scar resection and NeuroRegen scaffold trans-
plantation.  
SCI patient recovery 
Autonomic neural function was assessed after surgery. 
Sexual arousal was achieved in two cases, showing im-
proved penis reflex erection 2 month after surgery. Dimin-
ished sweating in skin below the injury level was partially 
recovered in three cases. More importantly, when low limb 
SSEP was performed, two cases began to show SSEP re-
covery at 6 months postoperatively with normal latency and 
lower amplitude, and this persisted until the end of the ob-
servation period (Table 4). 
DISCUSSION 
Five complete injury patients (ASIA A) were enrolled in 
this clinical study. Neural electrophysiological studies 
showed that there were no MEP detected in muscles below 
the injury level and no SSEP conducted from the ankle to 
the cortex through the injury level. Magnetic resonance im-
aging (MRI) showed complete injury in all five patients, 
confirming the total loss of motor or sensory functions be-
low the injury site. There is little evidence to support func-
tional recovery after complete SCI. Conventional treatments 
such as drug administration or rehabilitation exercises have 
no significant effects on neurological recovery in chronic 
SCI. 
SCI is mainly caused by trauma such as car accidents and 
falls, often initiating a cascade of biochemical reactions. 
Following the initial insult, a variety of inflammatory and 
cytotoxic mediators is released at the injured site, resulting 
in secondary damage to the spinal cord. This leads to con- 
Table 1  Patient demographic and clinical featuresa) 
Patient Sex Age Months post SCI SCI level ASIA grade
1 Male 27 2 T11-T12 A 
2 Male 53 14 C6-C7 A 
3 Male 51 7 T9-T10 A 
4 Female 56 32 T10-T12 A 
5 Male 29 10 T8-T9 A 
a) ASIA, American Spinal Injury Association; SCI, spinal cord injury. 
Table 2  Pre- and postoperative neural function assessmenta) 
Patient
Glial scar length 
(cm) 
ASIA grade Sensation level 
Before After Before After
1 2.8 A A T11 T11 
2 0.5 A A T3 T3 
3 3.5 A A T9 T9 
4 3.0 A A T10 T10 
5 4.5 A A T8 T8 
a) ASIA, American Spinal Injury Association. 
Table 3  Adverse effects assessment after surgery 
Complications Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Infection − − − − −
Increased level of C-reactive 
protein − − − − − 
Increased leukocytosis − − − − −
Allergic reaction or shock − − − − −
Perioperative complications − − − − −
Table 4  Pre- and postoperative SSEP assessmenta) 
Patient  
Before surgery 6 months after surgery
Latency Amplitude Latency Amplitude
4 Left tibial 
malleolus 




0 0 42.8 ms 0.43 μv 
a) SSEP, somatosensory evoked potential. 
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tinued and pervasive cell death and tissue damage. Fur-
thermore, astrocytes become hypertrophic in response to 
SCI and produce CSPGs that form a dense scar at the injury 
site. Many reports have demonstrated that glial scars are 
impediments to neural regeneration, making them primary 
targets for therapeutic strategies after SCI (Cregg et al., 
2014; Lukovic et al., 2015; Silver and Miller, 2004). Chon-
droitinase ABC (ChABC) can enzymatically digest the 
glycosaminoglycan side-chains of CSPGs, and ChABC 
treatment could improve glial scar digestion to reduce the 
lesion size and increase neural regeneration, which might 
further promote functional recovery in rat SCI (Barritt et al., 
2006; Bradbury and Carter, 2011; Zhao and Fawcett, 2013). 
However, studies assessing the efficacy of ChABC treat-
ment have only been performed in small animal models. 
Furthermore, ChABC has poor thermostability and is syn-
thesized from Escherichia coli; it may lose its enzymatic 
activity at body temperature and could carry immunological 
risk. Therefore, translating ChABC treatment into a clinical 
SCI therapy remains a challenge (Bradbury and Carter, 
2011; Tester et al., 2007). 
Surgical scar removal is a more direct approach to elim-
inating the inhibitory effect of scar tissue. Tabakow et al. 
removed yellowish scar tissue under an operating micro-
scope, but the glial scar was tightly connected with normal 
neural tissue, and it was difficult to accurately distinguish 
the scar from normal neural tissue under the microscope 
(Tabakow et al., 2014). MRI or functional MRI is consid-
ered the best method for determining the extent of spinal 
cord injury (Vedantam et al., 2014), but it has been reported 
that the MRI estimates of lesion length are not always con-
sistent with histological assessment in rat SCI (Ditor et al., 
2008). In our study, SSEP and MEP were used to determine 
the rostral and caudal edges of the scar tissue, respectively. 
By the neural electrophysiology method, the length of the 
scar was ascertained and removed. We found that the lesion 
length estimated by MRI was often smaller than intraopera-
tive neurophysiological monitoring results. No neurological 
deterioration or spine instability was detected after scar re-
section. The immunostaining results showed that the dis-
sected tissue mainly consisted of scar, and no nerve fibers 
or neural cells were detected in the tissue, which indicated 
that the scar was removed safely without further damaging 
neural function. Resecting the glial scar removes a physical 
and chemical barrier to neural regeneration and may pro-
mote neural repair. Thus, the length of scar was determined 
in vivo and it was safely removed under neural electrophys-
iology monitoring in complete SCI patients. For incomplete 
SCI patients, spontaneous plasticity events in spared neu-
ronal circuits may occur post-traumatically, including intact 
or injured axon collateral sprouting or synaptic rearrange-
ment (Onifer et al., 2011; Perez, 2015; Tansey, 2010), 
which may result in scar tissue mixed together with normal 
neural tissue. For this reason, dissecting scar tissue in in-
complete SCI patients is still a challenge.  
Collagen scaffolds are considered a suitable biomaterial 
for guiding neural regeneration because of their low anti-
genicity and excellent biocompatibility and biodegradabil-
ity. Different types of collagen scaffolds have been used to 
repair SCI in animal models, including collagen tubes, fi-
bers, membranes, and gels. A growing body of work shows 
that collagen scaffolds are suitable for guiding neural re-
generation (Sindou, 2001; Stang et al., 2005; Yoshii et al., 
2004). In our previous study, the NeuroRegen scaffold was 
prepared from bovine aponeurosis, which mainly consists of 
linearly ordered collagen fibers. When the scaffold was 
transplanted into complete SCI rat and canine models, it 
successfully guided neurite outgrowth along its fibers and 
decreased scar formation (Fan et al., 2010; Han et al., 2009; 
Han et al., 2010; Han et al., 2015; Li et al., 2013; Lin et al., 
2006). Based on these preclinical results, the clinical study 
was approved by the ethics committee and registered on the 
National Institute of Health database. All procedures per-
formed in this study were in accordance with the ethical 
standards of human clinical study. No obvious adverse 
symptoms related to the NeuroRegen scaffold transplanta-
tion were observed, such as infection, allergic reaction, or 
perioperative complications. The cerebrospinal fluid did not 
show any evidence of bacterial or fungal infection. In one 
case, a slight non-inflammatory fever was observed after 
surgery, but it was transient and did not exceed 38°C. After 
symptomatic treatment, the patient recovered within 72 h. 
These data show that NeuroRegen scaffold transplantation 
is safe. Our recent work demonstrated that NeuroRegen 
scaffold with mesenchymal stem cells could inhibit scar 
formation, induce newborn neuron production, and promote 
functional recovery after scar resection in complete tran-
sected chronic SCI rats and canines (unpublished data). 
Following scar tissue resection under electrophysiological 
monitoring in patients, the BMMCs and NeuroRegen scaf-
fold were transplanted into the spinal cord gap, where they 
could inhibit new scar formation and provide a suitable mi-
croenvironment to guide neural regeneration. 
Besides the total loss of motor and sensory function be-
low the injury site, autonomic dysfunction including ab-
normal blood pressure, heart rate control, sweating, and 
temperature dysregulation are common clinical conse-
quences of SCI. In our study, sexual arousal and diminished 
sweating were achieved in patients, indicating that auto-
nomic nervous system function was partially restored. More 
importantly, recovery of SSEP in tibial malleolus was de-
tected in two cases 6 months after surgery. These results 
showed that a certain degree of neural regeneration occurred 
following scar resection and NeuroRegen scaffold trans-
plantation. A longer observation time is necessary to assess 
the recovery of complete SCI after these procedures. 
We found that the lengths of the scars were diverse. The 
lengths of scars in the five SCI patients ranged from 0.5–4.5 
cm. Scar length was not directly correlated with the location 
of the injured segments or time post-SCI, but might be cor- 
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related with SCI patient constitution and injury severity. It 
has long been recognized that axonal regeneration is the 
main way to restore function after SCI. However, the rate of 
axonal elongation may be slower in the central nervous sys-
tem even under “regeneration enabled” circumstances than 
in the peripheral nervous system, in which the growth ve-
locity of regenerating peripheral nerves through the scar is 
0.25 mm per day. Furthermore, there is little evidence sup-
porting corticospinal tract (CST) growth into grafts or 
transplants (Tuszynski and Steward, 2012). It might be dif-
ficult to restore function by axonal regeneration after severe 
SCI in which the length of the scar is often more than one 
segment of spinal cord (2 cm). Our recent work showed that 
NeuroRegen scaffold with active factors increased neuronal 
differentiation of the transplanted or endogenous neural 
stem cells to produce different types of neurons throughout 
the lesion area. These newly generated relay neurons may 
further rebuild the synaptic connections with each other or 
with the host spinal neurons to improve locomotion out-
comes in SCI animals (Li et al., 2015; Li et al., 2013). Thus, 
rebuilding neuronal relays at the injury site would be a more 
efficient way to repair SCI compared with inducing axonal 
regrowth (Xiao et al., 2016). 
Following SCI, an inhibitory environment for neural re-
generation develops at the injury site. Many reports have 
demonstrated that scaffolds can rebuild the microenviron-
ment at the injured site. The NeuroRegen scaffold bridges 
the gap of the lesion and acts as a vehicle to deliver stem 
cells or biomolecules to promote neural regeneration. In our 
previous study, a functional biomaterial consisting of Neu-
roRegen scaffold, biologically active molecules (neu-
rotrophic factors or antagonists to myelin-associated inhibi-
tors), and stem cells was developed that greatly promoted 
neural regeneration and functional recovery in SCI animals 
(Han et al., 2010; Han et al., 2015; Li et al., 2015; Li et al., 
2013). In future work, biologically active molecules or stem 
cells could be added to the NeuroRegen scaffold for clinical 
SCI repair. 
MATERIALS AND METHODS 
Patient selection 
Five patients with complete SCI (ASIA Impairment Scale 
grade A) were included in this study in three hospitals: Af-
filiated Hospital of Logistics University of CAPF, The First 
Affiliated Hospital of Soochow University, and First Affili-
ated Hospital of PLA General Hospital. The main inclusion 
and exclusion criteria of the study were as follows: 
Inclusion Criteria 
(i) Male or female, 18–65 years old. (ii) Complete spinal 
cord injury at the cervical or thoracic level (C5-T12). (iii) 
ASIA A classification with no significant further improve-
ment. (iv) Patients signed informed consent. (v) Ability and 
willingness to regularly visit the hospital and follow-up 
during the study. 
Exclusion Criteria 
(i) Serious complications. (ii) History of life-threatening 
allergic or immune-mediated reaction. (iii) Clinically sig-
nificant abnormalities in routine laboratory examinations. 
(iv) Lactating and pregnant woman. (v) Participated in any 
other clinical trials within 3 months before enrollment. (vi) 
Poor compliance, difficultly completing the study require-
ments. 
Preparation and biological safety evaluation of 
the NeuroRegen scaffold 
NeuroRegen scaffolds were prepared from bovine aponeu-
rosis using previously described methods, with modifica-
tions (Lin et al., 2006). Briefly, fresh bovine aponeurosis 
were harvested and rinsed with cold distilled water, and 
residual muscles, connective tissue, and fat were carefully 
removed. The samples were treated with Tri (n-butyl) 
phosphate (TnBP), hypertonic solution, and enzyme to fur-
ther remove fat, cellular components, and soluble proteins. 
The samples were then repeatedly rinsed to completely re-
move the residual agents and freeze-dried. The scaffolds 
were critical point dried and sputter coated with gold prior 
to SEM imaging (S-3000N SEM; Hitachi, Japan). 
Acute toxicity, subchronic toxicity, allergen detection, 
genetic toxicity, intradermal irritation, cytotoxicity, hemo-
lytic toxicity, and degradability of the NeuroRegen scaffold 
were evaluated by the National Institute of Food and Drug 
Control according to Chinese Criterion of Medical Device 
GB16886. 
BMMC preparation 
Before the procedure, patients underwent tests for hematol-
ogy, blood biochemistry, urine microbiology, and screening 
for human immunodeficiency virus, human T-cell lympho-
tropic virus, Chagas disease, and hepatitis B and C. The 
isolation of BMMCs from bone marrow suspension was 
then performed. Bone marrow (50 mL) was harvested under 
local anesthesia from the posterior iliac crest and was im-
mediately heparinized. The bone marrow was then sedi-
mented using hydroxyethyl starch for erythrocyte reduction. 
Hydroxyethyl starch was added to the bone marrow until a 
final concentration of 3% was reached. After erythrocytes 
had sedimented, the upper cell suspension was collected 
into 50-mL tubes and centrifuged 700 g at 25°C for 10 min. 
The supernatant was discarded, and the cell suspension was 
washed with physiological salt solution. The BMMCs were 
diluted to a final volume of 0.5 mL and used for transplan-
tation. The cell number for transplantation was about 1×109 
cells. 
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Surgical and BMMC transplantation procedures 
After identification of the injury level with MRI, the patient 
was placed under general anesthesia in a prone position. A 
midline skin incision was made, followed by paravertebral 
muscle dissection and laminectomy. Under an operating 
microscope, an adhesion outside the injured dura was re-
moved. A midline durotomy was performed, followed by 
sharp dissection of the post-traumatic adhesions between 
the spinal cord surface and dura. The injury area mainly 
consisted of scar tissue and a cavity. The scar tissue was 
resected under nerve electrophysiology monitoring, and 
specimens were taken for histology. Next, BMMCs were 
added to the NeuroRegen scaffold and grafted into the tran-
sected spinal cord gap to bridge the defect. The dura was 
closed with absorbable sutures. 
Scar tissue resection under neural electrophysiology 
monitoring 
The texture of the scar tissue is different from the normal 
spinal cord structure, and the middle of the scar may have 
necrotic tissue or cavities. The boundaries of the normal 
spinal cord and scar tissue are generally determined ac-
cording to the neural electrophysiology (Figure 2C). SSEP 
and MEP were used to determine the rostral and caudal ends 
of the scar tissue, respectively. The stimulation electrodes of 
electromyography (XLTEK, Canada) were placed near the 
rostral side of the spinal cord injury site, and the recording 
electrodes were placed on the scalp before moving the stim-
ulation electrodes. If there was an SSEP response, the posi-
tion of the stimulation electrodes was on normal spinal cord 
tissue and if there was no SSEP response, the position was 
scar tissue. For caudal scar tissue, the stimulation electrodes 
were placed near the caudal end of the SCI, and the record-
ing electrodes were placed into the sphincter ani externus 
before moving the stimulation electrodes. If there was an 
MEP response, the position of the stimulation electrodes 
was normal spinal cord tissue, and if there was no MEP 
response, the position was scar tissue. After detecting the 
edge of the rostral and caudal ends of the scar tissue, the 
scar was dissected with an electronic knife and removed 
under the operating microscope. 
Immunocytochemistry  
Tissue samples taken from scar tissue were formalin-fixed 
overnight at 4°C and transferred to 20% sucrose (overnight 
at 4°C) and then 30% sucrose (72 h at 4°C). The samples 
were then embedded in Tissue-Tek O.C.T. compound (Sa-
kura Finetechnical Co., Japan) and sectioned on a cryostat 
set at 10-μm thickness (Leica Microsystems GmbH, Ger-
many). The slides were fixed in acetone for 15 min at 4°C 
and then incubated in phosphate-buffered saline (PBS) con-
taining 5% bovine serum albumin (BSA) with 0.1% Triton 
X-100 for 1 h at 25°C room temperature . The samples were 
incubated with primary antibodies overnight at 4°C: mouse 
monoclonal antibody against neurofilament 200 kDa (NF, 
1:200, ab3966, Abcam, UK), S100 protein (1:100, 
ZM-0224, ZSGB-Bio, China), βIII tubulin (Tuj-1, 1:500, 
05-559, Millipore, USA), nestin (1:500, MAB353, Milli-
pore), CSPG (1:500, ab11570, Abcam), and vimentin 
(1:500, V6630, Sigma, USA). They were then incubated 
with Alexa Fluor 568-conjugated donkey anti-mouse sec-
ondary antibody (A10037, 1:800, Invitrogen, USA) for 1 h 
at RT. Cell nuclei were stained with Hoechst 33342 
(1:1000, B2261, Sigma), and all images were taken with a 
Leica TCS SP8 confocal microscope. 
Patient follow-up 
Patients underwent rehabilitation for 6 months after surgery. 
Regular clinical and neurological assessments were per-
formed for at least 12 months. At each follow-up, complete 
clinical and neurological evaluations and ASIA Impairment 
Scale assessment were conducted before and 1, 3, 6, and 12 
months after surgery. SSEP testing was also carried out with 
tibial nerve stimulation for evaluation of the lower limbs, 
registration in the ankle, popliteal fossa, and scalp (Cz’ to 
Fpz) regions; the scalp electrodes were placed in the parietal 
and frontal regions for upper limb SSEP and at the vertex 
for lower limb SSEP. A 100-ms square wave electrical 
pulse was delivered at intensities strong enough to cause a 
thumb twitch. We identified a P40 potential in response to 
target stimuli that could affect early cortical SSEP. 
Compliance and ethics 
The author(s) declare that they have no conflict of interest. 
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